Compare PATK & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PATK | TARS |
|---|---|---|
| Founded | 1959 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | PATK | TARS |
|---|---|---|
| Price | $107.00 | $81.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $105.78 | $73.63 |
| AVG Volume (30 Days) | 254.1K | ★ 388.0K |
| Earning Date | 10-30-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $3,872,728,000.00 | $366,100,000.00 |
| Revenue This Year | $6.55 | $147.24 |
| Revenue Next Year | $5.08 | $53.11 |
| P/E Ratio | $30.76 | ★ N/A |
| Revenue Growth | 6.08 | ★ 182.44 |
| 52 Week Low | $72.99 | $38.51 |
| 52 Week High | $116.78 | $83.47 |
| Indicator | PATK | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 67.09 |
| Support Level | $104.86 | $77.44 |
| Resistance Level | $110.24 | $83.47 |
| Average True Range (ATR) | 3.45 | 3.62 |
| MACD | 0.60 | 0.12 |
| Stochastic Oscillator | 77.35 | 87.65 |
Patrick Industries Inc makes and sells building products and materials for recreational vehicles and manufactured housing. The company is organized into two segments based on product type: manufacturing and distribution. The manufacturing segment, which generates the majority of revenue, sells laminated and vinyl products that include furniture, shelving, cabinets, bath fixtures, and countertops. The distribution segment sells prefinished wall and ceiling panels, as well as electrical and plumbing products for the RV and manufactured housing industries. One of the firm's RV customers makes up a portion of revenue.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.